

Special Issue

Eye Genetics and Therapies

Message from the Guest Editors

Inherited eye diseases (IED) represent a vast spectrum of blinding genetic disorders affecting all cells and tissue types of the globe. The genetic mechanisms that underlie these diseases are extremely complex and diverse, with hundreds of genes and many thousands of disease variants reported to date. Current diagnostic testing is focused on targeted gene panel analysis, and can identify causative variants in up to 60%–80% of cases where a clear clinical indication is present. However, despite the huge advances in knowledge and technology since the discovery of the first disease variant some 30 years ago, patients without a clear indication are often left without a molecular diagnosis, thus restricting their access to effective clinical management, counselling, and emerging therapeutics.

Guest Editors

Dr. Kang Zhang
Dr. Ling Zhao
Dr. Wenbin Wei

Deadline for manuscript submissions

closed (30 September 2018)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/14942

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))